List view / Grid view
13 June 2016 | By Victoria White, Digital Content Producer
Novo Nordisk presented new findings from separate studies of Tresiba and semaglutide at the American Diabetes Association 76th Scientific Sessions...
10 June 2016 | By Victoria White, Digital Content Producer
Merck, known as MSD outside the US and Canada, has announced that it is is to acquire Afferent Pharmaceuticals...
10 June 2016 | By Victoria White, Digital Content Producer
Amgen's Blincyto (blinatumomab) demonstrated an almost two-times increase in median overall survival compared to standard of care...
10 June 2016 | By Victoria White, Digital Content Producer
A study shows that completely wiping out the immune system and then regenerating a new one can eliminate all signs of damaging brain inflammation in MS...
10 June 2016 | By CPhI
Key growth drivers for the MENA region were forecasted at CPhI Istanbul, with outsourcing, vaccine development and biotechnology emerging as major trends...
10 June 2016 | By Victoria White, Digital Content Producer
A study presented at EULAR showed that when antibodies develop in response to the infliximab, they also cross-react with the biosimilar of infliximab...
10 June 2016 | By Victoria White, Digital Content Producer
Data from the largest study of its kind confirm the long-term safety profile of Novartis’ Revolade in adults with chronic immune thrombocytopenia...
10 June 2016 | By Victoria White, Digital Content Producer
A Phase III trial shows daratumumab in combination with lenalidomide and dexamethasone achieved a 63% reduction in the risk of disease progression or death...
10 June 2016 | By
New data show promising results for venetoclax in patients with chronic lymphocytic leukaemia who have relapsed or become refractory (R/R) to treatment...
10 June 2016 | By Victoria White, Digital Content Producer
In a Phase Ib study, bimekizumab showed fast and sustained efficacy on disease activity measures in both skin and joints and was well-tolerated...
Lilly and Incyte have announced new data for baricitinib in rheumatoid arthritis (RA) at the Annual European Congress of Rheumatology (EULAR 2016).
9 June 2016 | By Victoria White, Digital Content Producer
Data demonstrating long-term comparable efficacy, safety and immunogenicity of Benepali (etanercept) and Flixabi (infliximab) have been presented at EULAR...
9 June 2016 | By Victoria White, Digital Content Producer
The Phase I/II study was designed to demonstrate the safety and tolerability of GS010 in 15 patients with Leber’s Hereditary Optic Neuropathy...
9 June 2016 | By Victoria White, Digital Content Producer
The programme will enable patients with serious fungal infections in EU states where the treatment is not yet commercially available to access isavuconazole...
9 June 2016 | By Victoria White, Digital Content Producer
Novartis has announced positive first results from a Phase II investigating the efficacy and safety of AMG 334 (erenumab) in chronic migraine prevention...
